Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality.


Journal

American journal of physiology. Regulatory, integrative and comparative physiology
ISSN: 1522-1490
Titre abrégé: Am J Physiol Regul Integr Comp Physiol
Pays: United States
ID NLM: 100901230

Informations de publication

Date de publication:
01 03 2021
Historique:
pubmed: 13 1 2021
medline: 11 3 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

The COVID19 pandemic has caused more than a million of deaths worldwide, primarily due to complications from COVID19-associated acute respiratory distress syndrome (ARDS). Controversy surrounds the circulating cytokine/chemokine profile of COVID19-associated ARDS, with some groups suggesting that it is similar to patients without COVID19 ARDS and others observing substantial differences. Moreover, although a hyperinflammatory phenotype associates with higher mortality in non-COVID19 ARDS, there is little information on the inflammatory landscape's association with mortality in patients with COVID19 ARDS. Even though the circulating leukocytes' transcriptomic signature has been associated with distinct phenotypes and outcomes in critical illness including ARDS, it is unclear whether the mortality-associated inflammatory mediators from patients with COVID19 are transcriptionally regulated in the leukocyte compartment. Here, we conducted a prospective cohort study of 41 mechanically ventilated patients with COVID19 infection using highly calibrated methods to define the levels of plasma cytokines/chemokines and their gene expressions in circulating leukocytes. Plasma IL1RA and IL8 were found positively associated with mortality, whereas RANTES and EGF negatively associated with that outcome. However, the leukocyte gene expression of these proteins had no statistically significant correlation with mortality. These data suggest a unique inflammatory signature associated with severe COVID19.

Identifiants

pubmed: 33434104
doi: 10.1152/ajpregu.00324.2020
pmc: PMC7938634
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

R250-R257

Subventions

Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : GM108538
Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : 1R01GM124133
Organisme : NHLBI NIH HHS
ID : R01 HL049426
Pays : United States
Organisme : HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : HL130704
Organisme : HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : 5R01HL049426
Organisme : NIGMS NIH HHS
ID : P41 GM108538
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM124133
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL130704
Pays : United States

Commentaires et corrections

Type : UpdateOf

Références

N Engl J Med. 2015 Feb 26;372(9):793-5
pubmed: 25635347
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953
pubmed: 32699149
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Intensive Care Med. 2019 Apr;45(4):516-519
pubmed: 30519902
J Pathol. 2021 Jan;253(1):31-40
pubmed: 32930394
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
Am J Respir Crit Care Med. 2019 Jul 1;200(1):42-50
pubmed: 30645145
Pediatr Pulmonol. 2008 Sep;43(9):851-7
pubmed: 18668691
Am J Physiol Lung Cell Mol Physiol. 2000 Jul;279(1):L75-80
pubmed: 10893205
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Crit Care Explor. 2020 Jun 22;2(6):e0144
pubmed: 32696007
medRxiv. 2020 Aug 18;:
pubmed: 32511515
Am J Respir Crit Care Med. 2019 Apr 15;199(8):980-986
pubmed: 30365341
Respir Res. 2002;3:2
pubmed: 11806837
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338
pubmed: 27513822
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10577-82
pubmed: 17563386
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Science. 1995 Dec 15;270(5243):1811-5
pubmed: 8525373
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201
pubmed: 33217246
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1850-6
pubmed: 8665045
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Respir Med. 2018 Sep;6(9):691-698
pubmed: 30078618
J Appl Physiol (1985). 1998 Sep;85(3):1004-10
pubmed: 9729576
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Am J Respir Crit Care Med. 2013 May 1;187(9):950-9
pubmed: 23449693
J Biol Chem. 2005 May 13;280(19):18579-89
pubmed: 15755725
Thorax. 2018 May;73(5):439-445
pubmed: 29477989
Lancet Respir Med. 2014 Aug;2(8):611-20
pubmed: 24853585
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11002-7
pubmed: 17569781
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
Intensive Care Med. 2018 Nov;44(11):1859-1869
pubmed: 30291376
Am J Physiol. 1994 Jan;266(1 Pt 1):L17-22
pubmed: 8304465
Crit Care Med. 2020 Aug;48(8):e657-e665
pubmed: 32697506
Biom J. 2010 Dec;52(6):708-21
pubmed: 21154895
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Am J Respir Crit Care Med. 2011 May 15;183(10):1380-90
pubmed: 21278303
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
JAMA Intern Med. 2021 Jan 1;181(1):32-40
pubmed: 33080017
Am J Respir Crit Care Med. 2015 Feb 1;191(3):309-15
pubmed: 25489881
Lancet Respir Med. 2016 Apr;4(4):259-71
pubmed: 26917434
Eur Respir J. 2009 Mar;33(3):543-50
pubmed: 19010984
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Thorax. 2017 Oct;72(10):876-883
pubmed: 28450529
Ann Intern Med. 1996 Aug 1;125(3):191-6
pubmed: 8686976
Crit Care Med. 1999 Feb;27(2):304-12
pubmed: 10075054
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1430-1434
pubmed: 32267160
Am J Respir Cell Mol Biol. 2020 Oct;63(4):541-543
pubmed: 32750259
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32501293

Auteurs

Joseph Balnis (J)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.
Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Alejandro P Adam (AP)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.
Department of Ophthalmology, Albany Medical College, Albany, New York.

Amit Chopra (A)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.

Hau C Chieng (HC)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.

Lisa A Drake (LA)

Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Nina Martino (N)

Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Ramon Bossardi Ramos (R)

Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Paul J Feustel (PJ)

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York.

Katherine A Overmyer (KA)

Morgridge Institute for Research, Madison, Wisconsin.

Evgenia Shishkova (E)

Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, Wisconsin.

Joshua J Coon (JJ)

Morgridge Institute for Research, Madison, Wisconsin.
Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, Wisconsin.

Harold A Singer (HA)

Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Marc A Judson (MA)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.

Ariel Jaitovich (A)

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York.
Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH